Foley & Lardner LLP represented Bioluminescence Ventures as the lead investor in the $50 million Series B funding extension for ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. With this final extension, ReCode raised a total of $260 million in Series B […]
The post Foley Represents Bioluminescence Ventures as Lead Investor in ReCode Therapeutics Series B Funding Extension appeared first on Legal Desire Media and Insights.